Tenaya Therapeutics (TNYA) Competitors $0.45 -0.01 (-2.58%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.46 +0.01 (+2.44%) As of 04/17/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. INMB, VYGR, ELDN, AMRN, IVA, MDWD, ACIU, RZLT, HURA, and NBTXShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include INmune Bio (INMB), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Amarin (AMRN), Inventiva (IVA), MediWound (MDWD), AC Immune (ACIU), Rezolute (RZLT), TuHURA Biosciences (HURA), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. INmune Bio Voyager Therapeutics Eledon Pharmaceuticals Amarin Inventiva MediWound AC Immune Rezolute TuHURA Biosciences Nanobiotix Tenaya Therapeutics (NASDAQ:TNYA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Which has more risk and volatility, TNYA or INMB? Tenaya Therapeutics has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Does the media prefer TNYA or INMB? In the previous week, INmune Bio had 5 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for INmune Bio and 0 mentions for Tenaya Therapeutics. INmune Bio's average media sentiment score of 0.38 beat Tenaya Therapeutics' score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media. Company Overall Sentiment Tenaya Therapeutics Neutral INmune Bio Neutral Does the MarketBeat Community believe in TNYA or INMB? INmune Bio received 102 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 84.00% of users gave Tenaya Therapeutics an outperform vote while only 76.60% of users gave INmune Bio an outperform vote. CompanyUnderperformOutperformTenaya TherapeuticsOutperform Votes4284.00% Underperform Votes816.00%INmune BioOutperform Votes14476.60% Underperform Votes4423.40% Do insiders and institutionals hold more shares of TNYA or INMB? 90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 35.2% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TNYA or INMB more profitable? Tenaya Therapeutics' return on equity of -86.17% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -86.17% -71.14% INmune Bio N/A -117.48%-78.96% Do analysts prefer TNYA or INMB? Tenaya Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 1,288.89%. INmune Bio has a consensus target price of $22.80, suggesting a potential upside of 211.48%. Given Tenaya Therapeutics' higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better earnings & valuation, TNYA or INMB? INmune Bio has higher revenue and earnings than Tenaya Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$124.08M-$1.32-0.34INmune Bio$14K11,989.11-$30.01M-$2.11-3.47 SummaryTenaya Therapeutics beats INmune Bio on 9 of the 17 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.41M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-0.3130.4821.8617.80Price / SalesN/A441.91380.5497.75Price / CashN/A168.6838.2634.64Price / Book0.223.466.453.98Net Income-$124.08M-$72.06M$3.22B$247.81M7 Day Performance-8.70%2.54%2.85%1.80%1 Month Performance-34.10%-15.71%-8.67%-6.81%1 Year Performance-89.51%-26.11%11.46%1.31% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.0535 of 5 stars$0.45-2.6%$6.25+1,288.9%-89.5%$39.41MN/A-0.31110Gap UpINMBINmune Bio1.9086 of 5 stars$7.17-1.4%$22.80+218.2%-13.2%$166.68M$14,000.00-3.3310Positive NewsGap DownVYGRVoyager Therapeutics4.4611 of 5 stars$2.99-3.1%$13.97+366.5%-59.2%$166.23M$80.00M4.24100Analyst RevisionGap DownELDNEledon Pharmaceuticals1.3167 of 5 stars$2.78-1.7%$12.50+349.2%+90.4%$165.81MN/A-1.3810Positive NewsAMRNAmarin0.2479 of 5 stars$0.40+0.1%N/A-50.3%$165.50M$228.61M-4.48360Analyst ForecastGap DownHigh Trading VolumeIVAInventiva1.6619 of 5 stars$3.13+1.8%$12.00+284.0%+4.3%$163.99M$9.20M0.00100Gap DownMDWDMediWound1.2266 of 5 stars$14.98+0.1%$31.33+109.2%-1.9%$161.19M$20.22M-5.1580ACIUAC Immune2.5357 of 5 stars$1.58-5.1%$12.00+661.9%-38.8%$158.15M$27.31M-3.42140Analyst RevisionNews CoveragePositive NewsRZLTRezolute2.8906 of 5 stars$2.60+2.8%$24.38+837.5%-15.1%$157.39MN/A-2.1340Positive NewsGap UpHURATuHURA BiosciencesN/A$3.59+6.2%$12.67+252.8%N/A$156.81MN/A0.00N/AAnalyst RevisionNews CoverageGap DownNBTXNanobiotix1.812 of 5 stars$3.32+1.6%$8.00+140.9%-37.9%$156.53M$36.22M0.00100 Related Companies and Tools Related Companies INmune Bio Competitors Voyager Therapeutics Competitors Eledon Pharmaceuticals Competitors Amarin Competitors Inventiva Competitors MediWound Competitors AC Immune Competitors Rezolute Competitors TuHURA Biosciences Competitors Nanobiotix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNYA Stock Free TNYA Stock Alerts